MAPKAPK2 and non-small cell lung carcinoma: Its associations with gastric cancer [53], breast cancer and two of the studied SNPs correlated significantly with cancer development [54] have been proved; RPS6 was declared closely relevant to the non-small cell lung cancer (NSCLC) [55], the renal cell carcinoma [56] and some other cancers [57, 58]; MAPKAPK2 was demonstrated to contribute to tumor progression by promoting M2 macrophage polarization and tumor angiogenesis [59].